These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 19480557)

  • 21. Differences in the induction of cytochrome P450 3A4 by taxane anticancer drugs, docetaxel and paclitaxel, assessed employing primary human hepatocytes.
    Nallani SC; Goodwin B; Buckley AR; Buckley DJ; Desai PB
    Cancer Chemother Pharmacol; 2004 Sep; 54(3):219-29. PubMed ID: 15175893
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The mycoestrogen zearalenone induces CYP3A through activation of the pregnane X receptor.
    Ding X; Lichti K; Staudinger JL
    Toxicol Sci; 2006 Jun; 91(2):448-55. PubMed ID: 16547076
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The pregnane X receptor binds to response elements in a genomic context-dependent manner, and PXR activator rifampicin selectively alters the binding among target genes.
    Song X; Xie M; Zhang H; Li Y; Sachdeva K; Yan B
    Drug Metab Dispos; 2004 Jan; 32(1):35-42. PubMed ID: 14709618
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2.
    Marathe P; Tang Y; Sleczka B; Rodrigues D; Gavai A; Wong T; Christopher L; Zhang H
    J Pharm Sci; 2010 Aug; 99(8):3579-93. PubMed ID: 20166197
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytochrome P450 3A Induction Predicts P-glycoprotein Induction; Part 1: Establishing Induction Relationships Using Ascending Dose Rifampin.
    Lutz JD; Kirby BJ; Wang L; Song Q; Ling J; Massetto B; Worth A; Kearney BP; Mathias A
    Clin Pharmacol Ther; 2018 Dec; 104(6):1182-1190. PubMed ID: 29569723
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytochrome P450 3A Induction Predicts P-glycoprotein Induction; Part 2: Prediction of Decreased Substrate Exposure After Rifabutin or Carbamazepine.
    Lutz JD; Kirby BJ; Wang L; Song Q; Ling J; Massetto B; Worth A; Kearney BP; Mathias A
    Clin Pharmacol Ther; 2018 Dec; 104(6):1191-1198. PubMed ID: 29569712
    [TBL] [Abstract][Full Text] [Related]  

  • 27. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
    Hendrikx JJ; Lagas JS; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
    Int J Cancer; 2013 May; 132(10):2439-47. PubMed ID: 23090875
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytochrome p450 3A4 messenger ribonucleic acid induction by rifampin in human peripheral blood mononuclear cells: correlation with alprazolam pharmacokinetics.
    Gashaw I; Kirchheiner J; Goldammer M; Bauer S; Seidemann J; Zoller K; Mrozikiewicz PM; Roots I; Brockmöller J
    Clin Pharmacol Ther; 2003 Nov; 74(5):448-57. PubMed ID: 14586385
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Temporal kinetics and concentration-response relationships for induction of CYP1A, CYP2B, and CYP3A in primary cultures of beagle dog hepatocytes.
    Graham RA; Tyler LO; Krol WL; Silver IS; Webster LO; Clark P; Chen L; Banks T; LeCluyse EL
    J Biochem Mol Toxicol; 2006; 20(2):69-78. PubMed ID: 16615094
    [TBL] [Abstract][Full Text] [Related]  

  • 30. P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans.
    Schuetz EG; Schinkel AH; Relling MV; Schuetz JD
    Proc Natl Acad Sci U S A; 1996 Apr; 93(9):4001-5. PubMed ID: 8633005
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Brain toxicity and inflammation induced in vivo in mice by the amyloid-β forty-two inducer aftin-4, a roscovitine derivative.
    Meunier J; Borjini N; Gillis C; Villard V; Maurice T
    J Alzheimers Dis; 2015; 44(2):507-24. PubMed ID: 25298201
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantitative relationship between rifampicin exposure and induction of Cyp3a11 in SXR humanized mice: extrapolation to human CYP3A4 induction potential.
    Kim S; Pray D; Zheng M; Morgan DG; Pizzano JG; Zoeckler ME; Chimalakonda A; Sinz MW
    Drug Metab Lett; 2008 Aug; 2(3):169-75. PubMed ID: 19356089
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regulation of cytochrome P450 2C9 expression in primary cultures of human hepatocytes.
    Sahi J; Shord SS; Lindley C; Ferguson S; LeCluyse EL
    J Biochem Mol Toxicol; 2009; 23(1):43-58. PubMed ID: 19202563
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetic-pharmacodynamic modeling of rifampicin-mediated Cyp3a11 induction in steroid and xenobiotic X receptor humanized mice.
    Raybon JJ; Pray D; Morgan DG; Zoeckler M; Zheng M; Sinz M; Kim S
    J Pharmacol Exp Ther; 2011 Apr; 337(1):75-82. PubMed ID: 21205914
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin.
    Kerbusch T; Jansen RL; Mathôt RA; Huitema AD; Jansen M; van Rijswijk RE; Beijnen JH
    Clin Pharmacol Ther; 2001 Aug; 70(2):132-41. PubMed ID: 11503007
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction of cytochrome P450 (CYP)1A1, CYP1A2, and CYP3A4 but not of CYP2C9, CYP2C19, multidrug resistance (MDR-1) and multidrug resistance associated protein (MRP-1) by prototypical inducers in human hepatocytes.
    Runge D; Köhler C; Kostrubsky VE; Jäger D; Lehmann T; Runge DM; May U; Stolz DB; Strom SC; Fleig WE; Michalopoulos GK
    Biochem Biophys Res Commun; 2000 Jun; 273(1):333-41. PubMed ID: 10873607
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In silico modeling for the nonlinear absorption kinetics of UK-343,664: a P-gp and CYP3A4 substrate.
    Abuasal BS; Bolger MB; Walker DK; Kaddoumi A
    Mol Pharm; 2012 Mar; 9(3):492-504. PubMed ID: 22264132
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
    Kamath AV; Wang J; Lee FY; Marathe PH
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):365-76. PubMed ID: 17429625
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol.
    Swaisland HC; Ranson M; Smith RP; Leadbetter J; Laight A; McKillop D; Wild MJ
    Clin Pharmacokinet; 2005; 44(10):1067-81. PubMed ID: 16176119
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects on metabolic clearance when administering a potent CYP3A autoinducer with the prototypic CYP3A inhibitor, ketoconazole.
    Ayan-Oshodi MA; Willis BA; Annes WF; Lowe SL; Friedrich S; de la Peña A; Zhang W; Brown T; Wise SD; Hall SD
    Drug Metab Dispos; 2012 Oct; 40(10):1945-52. PubMed ID: 22789530
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.